| First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2533 | 2017 |
| Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). DR Camidge, SHI Ou, G Shapiro, GA Otterson, LC Villaruz, ... Journal of Clinical Oncology 32 (15_suppl), 8001-8001, 2014 | 362 | 2014 |
| Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration A Drilon, JW Clark, J Weiss, SHI Ou, DR Camidge, BJ Solomon, ... Nature medicine 26 (1), 47-51, 2020 | 344 | 2020 |
| The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations—the Lung Cancer Mutation Consortium (LCMC2) DL Aisner, LM Sholl, LD Berry, MR Rossi, H Chen, J Fujimoto, AL Moreira, ... Clinical Cancer Research 24 (5), 1038-1047, 2018 | 192 | 2018 |
| IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain N Nogami, F Barlesi, MA Socinski, M Reck, CA Thomas, F Cappuzzo, ... Journal of Thoracic Oncology 17 (2), 309-323, 2022 | 177 | 2022 |
| PD-L1 testing in guiding patient selection for PD-1/PD-L1 inhibitor therapy in lung cancer K Ancevski Hunter, MA Socinski, LC Villaruz Molecular diagnosis & therapy 22, 1-10, 2018 | 171 | 2018 |
| Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD (L)-1 … JD Schoenfeld, A Giobbie-Hurder, S Ranasinghe, KZ Kao, A Lako, J Tsuji, ... The Lancet Oncology 23 (2), 279-291, 2022 | 147 | 2022 |
| The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement LC Villaruz, MA Socinski Clinical cancer research 19 (10), 2629-2636, 2013 | 147 | 2013 |
| Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis D Planchard, B Besse, HJM Groen, SMS Hashemi, J Mazieres, TM Kim, ... Journal of Thoracic Oncology 17 (1), 103-115, 2022 | 142 | 2022 |
| Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium LC Villaruz, MA Socinski, S Abberbock, LD Berry, BE Johnson, ... Cancer 121 (3), 448-456, 2015 | 132 | 2015 |
| Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non–small-cell lung cancer previously treated with immunotherapy—lung-MAP S1800A KL Reckamp, MW Redman, KH Dragnev, K Minichiello, LC Villaruz, ... Journal of Clinical Oncology 40 (21), 2295-2307, 2022 | 123 | 2022 |
| Crizotinib in patients with MET-amplified NSCLC DR Camidge, GA Otterson, JW Clark, SHI Ou, J Weiss, S Ades, GI Shapiro, ... Journal of Thoracic Oncology 16 (6), 1017-1029, 2021 | 115 | 2021 |
| Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts AC. SM Gadgeel, J Stevenson, CJ Langer, L Gandhi, H Borghaei, A Patnaik, ... Journal of Clinical Oncology 34 (15_suppl), 9016-9016, 2016 | 98 | 2016 |
| Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial. DR Camidge, GA Otterson, JW Clark, SHI Ou, J Weiss, S Ades, U Conte, ... Journal of Clinical Oncology 36 (15_suppl), 9062-9062, 2018 | 87 | 2018 |
| Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study SM Gadgeel, JP Stevenson, CJ Langer, L Gandhi, H Borghaei, A Patnaik, ... Lung Cancer 125, 273-281, 2018 | 85 | 2018 |
| Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H MA Gubens, LV Sequist, JP Stevenson, SF Powell, LC Villaruz, ... Lung Cancer 130, 59-66, 2019 | 81 | 2019 |
| LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid … SV Liu, LC Villaruz, VHF Lee, VW Zhu, CS Baik, A Sacher, CE McCoach, ... Annals of Oncology 31, S1189, 2020 | 75 | 2020 |
| ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma S Dacic, LC Villaruz, S Abberbock, A Mahaffey, P Incharoen, ... Oncotarget 7 (50), 82943, 2016 | 66 | 2016 |
| The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma LC Villaruz, MA Socinski, DE Cunningham, SI Chiosea, TF Burns, ... Cancer 119 (12), 2268-2274, 2013 | 66 | 2013 |
| The role of anti-angiogenesis in non-small-cell lung cancer: an update LC Villaruz, MA Socinski Current oncology reports 17, 1-13, 2015 | 61 | 2015 |
